{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:33:24Z","timestamp":1781015604863,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.drugalcdep.2015.06.032","type":"journal-article","created":{"date-parts":[[2015,7,4]],"date-time":"2015-07-04T14:40:09Z","timestamp":1436020809000},"page":"125-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection"],"prefix":"10.1016","volume":"154","author":[{"given":"Heather","family":"Valerio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lewsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther J.","family":"Aspinall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bramley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Innes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J.","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0005","doi-asserted-by":"crossref","first-page":"12722","DOI":"10.3748\/wjg.v20.i36.12722","article-title":"Eligibility of persons who inject drugs for treatment of hepatitis C virus infection","volume":"20","author":"Arain","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who actively inject drugs: a systematic review and meta-analysis","volume":"57","author":"Aspinall","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0015","series-title":"Members\u2019 Debate on Hepatitis C","author":"Chisholm","year":"2004"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0020","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1086\/427449","article-title":"Follow up studies of treatment for hepatitis C virus infection among injection drug users","volume":"40","author":"Dalgard","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0025","series-title":"EASL Recommendations on Treatment of Hepatitis C","author":"EASL","year":"2015"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/cid\/cit301","article-title":"Hepatitis C reinfection following treatment among people who use drugs","volume":"57","author":"Grady","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0035","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1440-1746.2010.06238.x","article-title":"Reinfection with hepatitis C virus following sustained virological response in injection drug users","volume":"25","author":"Grebely","year":"2009","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0040","series-title":"Hepatitis C in UK: Annual Report","author":"Health Protection Agency","year":"2013"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2334-8-120","article-title":"Frequency, factors, and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England","volume":"8","author":"Hope","year":"2008","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0055","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/hep.26051","article-title":"Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness","volume":"57","author":"Innes","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0060","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/MEG.0b013e32835201a4","article-title":"Ranking predictors of sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland","volume":"24","author":"Innes","year":"2012","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0065","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.24561","article-title":"Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care","volume":"54","author":"Innes","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0070","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27766","article-title":"Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes","author":"Innes","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0075","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3201\/eid1310.061196","article-title":"Skin and soft tissue infection and vascular disease among drug users","volume":"13","author":"Irish","year":"2007","journal-title":"Engl. Emerg. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0080","series-title":"Australian NSP Survey National Data Report 2007\u20132011: Prevalence of HIV, HCV and Injecting and Sexual Behaviour among NSP Attendees","author":"Iversen","year":"2012"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0085","first-page":"72","article-title":"The Scottish record linkage system","volume":"51","author":"Kendrick","year":"1993","journal-title":"Health Bull. (Edinb.)"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/1471-2458-8-405","article-title":"Risk factors for developing cutaneous injection-related infection among injection drug users: a cohort study","volume":"8","author":"Lloyd-Smith","year":"2008","journal-title":"BMC Public Health"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.24656","article-title":"Cost effectiveness of hepatitis C virus antiviral treatment for injection drug user populations","volume":"55","author":"Martin","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0100","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jhep.2010.08.029","article-title":"Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations?. A modelling analysis of its prevention utility","volume":"54","author":"Martin","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0105","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0110","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0140-6736(08)61311-2","article-title":"Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review","volume":"372","author":"Mathers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0115","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.bjc.6604563","article-title":"A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland","volume":"99","author":"McDonald","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0120","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12153","article-title":"Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan","author":"McDonald","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0125","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0130","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF02351499","article-title":"The social determinants of emergency department and hospital use by injection drug users in Canada","volume":"76","author":"Palepu","year":"1999","journal-title":"J. Urban Health"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0135","first-page":"415","article-title":"Hospital utilization and costs in a cohort of injecting drug users","volume":"165","author":"Palepu","year":"2001","journal-title":"CMAJ"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0140","series-title":"Hepatitis C Action Plan for Scotland: Phase II: May 2008\u2013March 2011","author":"Scottish Government Health Department","year":"2008"},{"key":"10.1016\/j.drugalcdep.2015.06.032_bib0145","author":"University of the West of Scotland","year":"2015"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871615003312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871615003312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:56:47Z","timestamp":1537491407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871615003312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":28,"alternative-id":["S0376871615003312"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.06.032","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}